Sweden - OHE

We found for

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

Read more

Are Recommendations for HTA of Gene Therapies Being Achieved?

Read more

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Read more

© WellcomeCollection

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Read more

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Read more

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

Read more

International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective

Read more

Value Based Pricing in Sweden: Lessons for Design?

Read more

Health Policy and Regulation

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

Read more